Paper32508653
Discovering Anti-Cancer Drugs via Computational Methods.
Cui W and 5 others. Front Pharmacol, 2020. Cited by 173 papers, by iCite.
Cite this record
ConductScience Library. Discovering Anti-Cancer Drugs via Computational Methods. Papers, record 32508653. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/32508653
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
References120
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 23651482 | Methods and applications of structure based pharmacophores in drug discovery. | Curr Top Med Chem | 2013 | https://conductscience.org/library/papers/23651482 | PubMed |
| 2 | 18274745 | EANM procedure guidelines for 131I-meta-iodobenzylguanidine (131I-mIBG) therapy. | Eur J Nucl Med Mol Imaging | 2008 | https://conductscience.org/library/papers/18274745 | PubMed |
| 3 | 30230381 | Executive functions and health behaviors associated with the leading causes of death in the United States: A systematic review. | J Health Psychol | 2020 | https://conductscience.org/library/papers/30230381 | PubMed |
| 4 | 31320117 | Advancing Drug Discovery via Artificial Intelligence. | Trends Pharmacol Sci | 2019 | https://conductscience.org/library/papers/31320117 | PubMed |
| 5 | 27019343 | Deciphering the Complexity of Ligand-Protein Recognition Pathways Using Supervised Molecular Dynamics (SuMD) Simulations. | J Chem Inf Model | 2016 | https://conductscience.org/library/papers/27019343 | PubMed |
| 6 | 24591595 | Identifying the macromolecular targets of de novo-designed chemical entities through self-organizing map consensus. | Proc Natl Acad Sci U S A | 2014 | https://conductscience.org/library/papers/24591595 | PubMed |
| 7 | 31710991 | In silico design, synthesis and activity of potential drug-like chrysin scaffold-derived selective EGFR inhibitors as anticancer agents. | Comput Biol Chem | 2019 | https://conductscience.org/library/papers/31710991 | PubMed |
| 8 | 16175177 | HSP90 and the chaperoning of cancer. | Nat Rev Cancer | 2005 | https://conductscience.org/library/papers/16175177 | PubMed |
| 9 | 31902900 | Drug Discovery Researches on Modulators of Lysine-Modifying Enzymes Based on Strategic Chemistry Approaches. | Chem Pharm Bull (Tokyo) | 2020 | https://conductscience.org/library/papers/31902900 | PubMed |
| 10 | 17016424 | Discovery and development of sorafenib: a multikinase inhibitor for treating cancer. | Nat Rev Drug Discov | 2006 | https://conductscience.org/library/papers/17016424 | PubMed |
| 11 | 26205061 | Molecular docking and structure-based drug design strategies. | Molecules | 2015 | https://conductscience.org/library/papers/26205061 | PubMed |
| 12 | 16756493 | Structure and mechanism of the Hsp90 molecular chaperone machinery. | Annu Rev Biochem | 2006 | https://conductscience.org/library/papers/16756493 | PubMed |
| 13 | 7990113 | Molecular similarity indices in a comparative analysis (CoMSIA) of drug molecules to correlate and predict their biological activity. | J Med Chem | 1994 | https://conductscience.org/library/papers/7990113 | PubMed |
| 14 | 30209701 | Ivosidenib: First Global Approval. | Drugs | 2018 | https://conductscience.org/library/papers/30209701 | PubMed |
| 15 | 27362234 | Allosteric coupling from G protein to the agonist-binding pocket in GPCRs. | Nature | 2016 | https://conductscience.org/library/papers/27362234 | PubMed |
| 16 | 30155234 | Large-scale comparison of machine learning methods for drug target prediction on ChEMBL. | Chem Sci | 2018 | https://conductscience.org/library/papers/30155234 | PubMed |
| 17 | 16567363 | GBPM: GRID-based pharmacophore model: concept and application studies to protein-protein recognition. | Bioinformatics | 2006 | https://conductscience.org/library/papers/16567363 | PubMed |
| 18 | 29247830 | Phase 2 Study of the HSP-90 Inhibitor AUY922 in Previously Treated and Molecularly Defined Patients with Advanced Non-Small Cell Lung Cancer. | J Thorac Oncol | 2018 | https://conductscience.org/library/papers/29247830 | PubMed |
| 19 | 30721452 | Gilteritinib: First Global Approval. | Drugs | 2019 | https://conductscience.org/library/papers/30721452 | PubMed |
| 20 | 31372957 | Entrectinib: First Global Approval. | Drugs | 2019 | https://conductscience.org/library/papers/31372957 | PubMed |
Cited by103
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 173 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42798927 | Integrating Machine Learning Approaches and Topological Indices for Prediction of Electronic Properties in Anticancer Drugs. | ACS Omega | 2026 | https://conductscience.org/library/papers/42798927 | PubMed |
| 42757169 | Targeting cancer hallmarks with microbiome-derived bacteriocins and postbiotics: molecular mechanisms and translational opportunities in oncology. | Front Oncol | 2026 | https://conductscience.org/library/papers/42757169 | PubMed |
| 42591656 | Virtual screening identifies specnuezhenide as a potential therapeutic agent for rosacea via KLK5/TLR4/NF-κB pathway inhibition and metabolic modulation. | Front Immunol | 2026 | https://conductscience.org/library/papers/42591656 | PubMed |
| 42367280 | Analysis of the interaction network relationship between drugs using a graph neural network. | Front Pharmacol | 2026 | https://conductscience.org/library/papers/42367280 | PubMed |
| 42360583 | Machine learning-driven prioritization and experimental validation of traditional Chinese medicine-derived STING-inhibitory candidates. | Mol Divers | 2026 | https://conductscience.org/library/papers/42360583 | PubMed |
| 42234666 | In silico characterization of bioactive phytochemicals as antivirals targeting the reovirus σ1 protein for inhibiting σ1-mediated host cell entry. | PLoS One | 2026 | https://conductscience.org/library/papers/42234666 | PubMed |
| 42105068 | Machine Learning-driven Prediction of Cervical Cancer Cell Viability After Treatment With Thymoquinone, Curcumin, and 5-Fluorouracil. | Appl Biochem Biotechnol | 2026 | https://conductscience.org/library/papers/42105068 | PubMed |
| 41793680 | Quinoxaline as Dual Modulators of Apoptotic Regulators Bcl-2 and Bax: A Combined In Vitro and In Silico Anticancer Approach. | Asian Pac J Cancer Prev | 2026 | https://conductscience.org/library/papers/41793680 | PubMed |
| 41566300 | Chemical constituents of Rhazya stricta as potential Aurora kinase A inhibitors for targeting HER2-negative breast cancer: an integrated in-silico and in-vitro study. | BMC Complement Med Ther | 2026 | https://conductscience.org/library/papers/41566300 | PubMed |
| 41524971 | AI-driven peptide discovery for endometrial cancer: deep generative modeling and molecular simulation in the big data era. | J Comput Aided Mol Des | 2026 | https://conductscience.org/library/papers/41524971 | PubMed |
| 41471329 | Synthetic Linear Lipopeptides and Lipopeptoids Induce Apoptosis and Oxidative Stress: In Vitro Cytotoxicity and SAR Evaluation Against Cancer Cell Lines. | Pharmaceuticals (Basel) | 2025 | https://conductscience.org/library/papers/41471329 | PubMed |
| 41460364 | Needle-in-a-haystack approach: rapid screening of PDE1C inhibitors through the combination of machine learning, molecular docking, molecular dynamics simulations and experimental validation. | J Comput Aided Mol Des | 2025 | https://conductscience.org/library/papers/41460364 | PubMed |
| 41426052 | Synthesis and anticancer potential of glycosides. | RSC Adv | 2025 | https://conductscience.org/library/papers/41426052 | PubMed |
| 41335181 | Design, synthesis, characterization, computational analysis, structure-activity relationship, and investigation of the anticancer potential of novel dibromodibenzoazepine-based hybrid structures. | Mol Divers | 2026 | https://conductscience.org/library/papers/41335181 | PubMed |
| 41312951 | In Silico and In Vitro Evaluation of Novel Small Molecule Inhibitors Targeting Apoptosis Pathways in Breast Cancer Cells. | Asian Pac J Cancer Prev | 2025 | https://conductscience.org/library/papers/41312951 | PubMed |
| 41183148 | Exploring Artificial Intelligence's Potential to Enhance Conventional Anticancer Drug Development. | Drug Dev Res | 2025 | https://conductscience.org/library/papers/41183148 | PubMed |
| 41009411 | Quercetin and Its Structural Analogs as NUDT5 Inhibitors: A Preliminary In Silico Study. | Int J Mol Sci | 2025 | https://conductscience.org/library/papers/41009411 | PubMed |
| 41006418 | Identification of novel small molecule inhibitors targeting multiple methyltransferase like proteins against hepatocellular carcinoma. | Sci Rep | 2025 | https://conductscience.org/library/papers/41006418 | PubMed |
| 40849528 | Porphyrinic MOF-derived novel nanocomposite for gastric anticancer and Helicobacter pylori photoantibacterial effect assay. | Sci Rep | 2025 | https://conductscience.org/library/papers/40849528 | PubMed |
| 40678483 | Advances and challenges in drug design against dental caries: Application of in silico approaches. | J Pharm Anal | 2025 | https://conductscience.org/library/papers/40678483 | PubMed |
Genes19
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/32508653
GET https://conductscience.org/api/papers/v1/32508653/references?page=2